OncoMatch/Clinical Trials/NCT07059221
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Is NCT07059221 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SHR-A2102 and Adebrelimab for recurrent/metastatic head and neck squamous cell carcinoma.
Treatment: SHR-A2102 · Adebrelimab · Cetuximab — The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102 for n Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
At least one measurable lesion according to RECIST v1.1 criteria. Locally advanced patients who are candidates for curative surgery or local therapy and have the intention to undergo such treatment [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational drug
Exception: within 4 weeks before the first dose
Use of any investigational drug within 4 weeks before the first dose
Cannot have received: anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, targeted therapy, etc.)
Exception: last dose within 4 weeks before the first dose; for small-molecule targeted drugs, within 2 weeks or 5 half-lives (whichever is longer); traditional Chinese medicine with antitumor indications within 2 weeks before the first dose
Last dose of anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, targeted therapy, etc.) within 4 weeks before the first dose; for small-molecule targeted drugs, within 2 weeks or 5 half-lives (whichever is longer); traditional Chinese medicine with antitumor indications within 2 weeks before the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify